ARWR Arrowhead Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARWR

Price (delayed)

$47.02

Market cap

$4.98B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.47

Enterprise value

$4.92B

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger ...

Highlights
The quick ratio has increased by 23% YoY and by 12% from the previous quarter
The equity has grown by 3.9% YoY
The gross profit has soared by 132% YoY but it is down by 5% QoQ
The company's revenue has surged by 132% YoY but it fell by 5% QoQ
The net income has declined by 38% since the previous quarter and by 22% year-on-year
ARWR's EPS is down by 36% from the previous quarter and by 20% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://arrowheadpharma.com
Peers: ALNY INO JNJ LGND

Key stats

What are the main financial stats of ARWR
Market
Shares outstanding
105.85M
Market cap
$4.98B
Enterprise value
$4.92B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.95
Price to sales (P/S)
19.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.68
Earnings
Revenue
$249.94M
EBIT
-$160.04M
EBITDA
-$149.78M
Free cash flow
-$119.85M
Per share
EPS
-$1.47
Free cash flow per share
-$1.13
Book value per share
$4.29
Revenue per share
$2.36
TBVPS
$6.99
Balance sheet
Total assets
$751.78M
Total liabilities
$277.61M
Debt
$81.11M
Equity
$453.93M
Working capital
$304.18M
Liquidity
Debt to equity
0.18
Current ratio
3.37
Quick ratio
3.25
Net debt/EBITDA
0.39
Margins
EBITDA margin
-59.9%
Gross margin
100%
Net margin
-61.6%
Operating margin
-63.8%
Efficiency
Return on assets
-22%
Return on equity
-36.5%
Return on invested capital
-34.5%
Return on capital employed
-25.7%
Return on sales
-64%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARWR stock price

How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
2.31%
1 week
12.57%
1 month
12.68%
1 year
-27.43%
YTD
-29.08%
QTD
33.54%

Financial performance

How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$249.94M
Gross profit
$249.94M
Operating income
-$159.56M
Net income
-$153.93M
Gross margin
100%
Net margin
-61.6%
The gross profit has soared by 132% YoY but it is down by 5% QoQ
The company's revenue has surged by 132% YoY but it fell by 5% QoQ
The operating margin has increased by 49% year-on-year but it has declined by 42% since the previous quarter
Arrowhead Pharmaceuticals's net margin has increased by 47% YoY but it has decreased by 45% QoQ

Growth

What is Arrowhead Pharmaceuticals's growth rate over time

Valuation

What is Arrowhead Pharmaceuticals stock price valuation
P/E
N/A
P/B
10.95
P/S
19.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.68
ARWR's EPS is down by 36% from the previous quarter and by 20% YoY
The price to book (P/B) is 20% lower than the last 4 quarters average of 13.4 and 3.5% lower than the 5-year quarterly average of 11.1
The equity has grown by 3.9% YoY
The company's revenue has surged by 132% YoY but it fell by 5% QoQ
The price to sales (P/S) is 54% less than the 5-year quarterly average of 41.9 and 39% less than the last 4 quarters average of 32.0

Efficiency

How efficient is Arrowhead Pharmaceuticals business performance
ARWR's ROS is up by 49% YoY but it is down by 43% from the previous quarter
The company's return on assets fell by 38% QoQ and by 10% YoY
The company's return on equity fell by 36% QoQ and by 30% YoY
Arrowhead Pharmaceuticals's return on invested capital has increased by 28% YoY but it has decreased by 12% QoQ

Dividends

What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARWR.

Financial health

How did Arrowhead Pharmaceuticals financials performed over time
ARWR's total assets is 171% higher than its total liabilities
The company's current ratio rose by 25% YoY and by 12% QoQ
The quick ratio has increased by 23% YoY and by 12% from the previous quarter
Arrowhead Pharmaceuticals's debt is 82% lower than its equity
The debt to equity has soared by 200% from the previous quarter and by 200% YoY
The equity has grown by 3.9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.